Clay Siegall was responsible for founding Seattle Genetics in 1998. He is the President, Board Chairman, and Chief executive officer of the company built on a foundation of rigorous research, scientific innovations and the passion of assisting patients. Clay is a scientist by training and has the ambition and emphasis on cancer therapies, and this led him to build the company. Mr. Clay has guided the company to become one of the leading companies in developing antibody-drug conjugates.
He also led the company to secure the FDA approval in 2011 of ADCETRIS which was the company’s first ADC product. With collaborating with Takeda Pharmaceuticals, the drug ADCETRIS has become a global brand where it has been approved in more than fifty countries. Under his leadership of Siegall, Seattle Genetics is advancing a pipeline of ADCs proprietary to help in treating cancer.
Before co-founding Seattle Genetics, Dr. Clay worked with Bristol-Myers Squibb Pharmaceutical Research Institute for nearly six years since 1991. After leaving the research institute, Siegall joined the National Cancer Institute for three years as from 1988. While working in these facilities, Clay gained a lot of experiences that came in handy when he was founding the Seattle Genetics company.
He also has worked on the Board of Directors of various institutions such as Washington Roundtable, Ultragenyx Pharmaceuticals and Alder BioPharmacceuticals which sharpened his leadership skills and opened him to the field of medicine.
A good leader is expected to always lead his team to success and advancements. Siegall has led the company into entering multiple strategic licenses for the sake of the company’s ADC technology seen to generate more than three hundred million dollars from the time it was founded. Some of these strategic licenses include AbbVie, Pfizer, GlaxoSmithKline, and Genentech.
Across various internal and collaborator programs, more than twenty ADCs clinics employ the Seattle Genetics’ technology. With the help of Dr. Siegall, the firm has engaged in capital-raising activities where they have been in a position of securing more than two billion dollars through private and public financings. The 2001 public offering also played a part in financing the firm. Dr. Siegall has played a very crucial role in helping the cancer patients.